Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA
Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )
28 Oct 2024

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )
28 Oct 2024

Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan

Dr Muhammad Usman Rashid - Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan
Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan ( Dr Muhammad Usman Rashid - Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan )
23 Oct 2024

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )
16 Oct 2024

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
30 Sep 2024

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )
30 Sep 2024

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )
19 Sep 2024

PFS increase but no OS increase for niraparib in advanced ovarian cancer

Dr Antonio González-Martín - Cancer Center Clínica Universidad de Navarra, Madrid, Spain
PFS increase but no OS increase for niraparib in advanced ovarian cancer ( Dr Antonio González-Martín - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )
17 Sep 2024

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024